ATTAIN-1: Oral Orforglipron Reduced Weight in Obesity
ATTAIN-1 found that oral orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks in adults with obesity without diabetes.
Hormone Insight
Evidence summaries in diabetes, endocrinology, and metabolism for clinicians who need the key data fast.
Latest Evidence
View all PICO summaries
CHIRACIC Trial: Adrenalectomy Reduced Treatment Burden in MACS-Associated Hypertension
In CHIRACIC, adrenalectomy improved home-blood-pressure normotension with less medication versus conservative management in unilateral mild autonomous cortisol secretion-associated hypertension.
Monthly Self-Injected Octreotide Depot Maintained Control in Acromegaly
In ACROINNOVA 1, monthly self-injected CAM2029 maintained IGF-1 control in 72.2% of adults with controlled acromegaly versus 37.5% on placebo withdrawal.
STEP UP: Semaglutide 7.2 mg Delivered Additional Weight Loss in Obesity
In STEP UP, semaglutide 7.2 mg reduced body weight by 18.7% versus 3.9% with placebo and outperformed semaglutide 2.4 mg in adults with obesity without diabetes.
Weekly Methotrexate Increased Antithyroid-Drug Withdrawal in Graves Disease
In an open-label Graves disease RCT, methotrexate 10 mg weekly added to methimazole increased treatment withdrawal at 18 months, but remains investigational.
Oral Agents Did Not Match Insulin for Gestational Diabetes Outcomes
In gestational diabetes requiring medication, metformin-first oral therapy with glyburide rescue did not prove noninferior to insulin for preventing large-for-gestational-age birth.
Zoledronate Every 5 Years Reduced Vertebral Fractures in Early Postmenopausal Women
In early postmenopausal women aged 50 to 60 years, zoledronate at baseline and 5 years reduced 10-year morphometric vertebral fractures from 11.1% to 6.3%.
Dapagliflozin Plus Calorie Restriction Increased Type 2 Diabetes Remission in Early Disease
In overweight or obese adults with early type 2 diabetes, dapagliflozin added to calorie restriction increased 12-month remission from 28% to 44%.